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Introduction  
In December 2019, the new noronavirus (COVID-19) 
burst occurred in China.1,2 Chinese governments 
announced new undetermined etiology subjects of 
pneumonia.3 At first, all patients were concentrated into 
the wholesale market of Wuhan seafood. It was reported a 
pandemic by the World Health Organization (WHO), on 
11 March 2020. There are far beyond 8 million validated 
COVID-19 cases beside 700,000 deaths worldwide as of 
August 16, 2020.4,5 
COVID-19 created a vast deal of importance amid 
researchers, scientists, and physicians around the world.6 
The volume of work being performed and the quantity of 
papers written on COVID-19 is unparalleled. Hundreds 
of manuscripts were estimated to be published upon 
this subject from the beginning of the year.7 Data have 
begun to emerge on various features of prevention, 
transmission, pathology, disease manifestations, and 
management strategies.8-10 Although COVID-19 has a 
beneficial effect on the respiratory and cardiovascular 
system, many COVID-19 patients are additionally 
prone to neurological manifestations (such as neuralgia, 
hypogeusia, dizziness, and headache) and complexities 
including acute cerebrovascular diseases, encephalopathy, 
skeletal muscle injury, and impaired consciousness.11,12
We are offering a systematic study of COVID-19’s 
clinical manifestations and complications. They aim 
to educate the neurologists, and doctors dealing with 
presumed COVID-19 patients on potential neurological 
symptoms and the likely neurological problems arising 
from this novel infection with the virus.
Literature Search Strategy 
We searched PubMed Central, Medline, and Google 
scholar using the keywords “pandemic”, “ COVID-19”, 
“neurology”, “complications”, “SARS- COV-2”, 
“Coronavirus”, and “manifestations”. Single English 
language scripts without time-end were looking. The 
latest scan of the literature was conducted on August 
1st, 2020. It is essential to remember that fresh data are 
frequently exchanged and so considerably it consists 
generally of preprints, small case collection, case reports, 
and part of an article discussing COVID-19 clinical 
characteristics. Most of the COVID-19 evidence is 
released from Wuhan city, China.13 At the time of writing 
this paper, we were capable to find in-depth hardly 34 
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full-text papers in English language biomedical paper 
identifying precisely the complications and neurological 
features of COVID-19. Figure 1 demonstrate the diagram 
of how we end up in reviewing of only 34 full-text articles.
Mechanism of Central Nervous System Aggression 
COVID-19 does not have ample trial evidence accessible, 
however, it is thought a mutated version of the Middle East 
respiratory syndrome  (MERS) virus and, the severe acute 
respiratory syndrome (SARS) virus.14 Consequently it is 
supposed to perform similarly.15 Coronaviruses are not 
mainly neurotropic, so their main aim is the respiratory 
epithelium. The enzyme-2 receptor (ACE 2) that converts 
angiotensin is believed to be the purpose receptor for 
cell adjunction and following internalization. Following 
the entry within the cell, the SARS-CoV-2 RNA is 
subsequently translated and replicated in the cytoplasm, 
the virus is delivered in blood circulation after the 
development of envelope protein and the inclusion of RNA 
within it.16 Therefore it will bind, multiply, and destroy 
the tissue of the neurons. Animal studies in rats show 
that severe acute respiratory syndrome (SARS-CoV-2) 
penetrates the central nervous system (CNS) within a 
retrograde transference by the cribriform bone or via the 
olfactory epithelium enters the brain within seven days. 
Second, disruption of the blood-brain barrier provokes 
the virus to access the brain right during the viremia 
phase of the disease. The extra assumed mechanism is the 
aggression by SARS-CoV-2 of peripheral nerve termini 
which next reaches the CNS within the linked track to 
the synapse. Therefore, because COVID-19 has parallels 
with SARS-CoV-2, this can be concluded that it more fits 
the corresponding CNS invasion pathways as explained 
earlier.
Neuropathological Mechanism of Central Nervous 
System Impairment 
COVID-19 is likely to result in two mechanisms of 
neurological damage; hypoxic brain damage and immune-
mediated CNS injury.
Hypoxic Brain Associated Damage 
Uncompromising pneumonia can lead to systemic 
hypoxia which damages the CNS. The risk factors 
include hypercarbia, peripheral vasodilatation, anaerobic 
metabolism with toxic compound accumulation, hypoxia. 
This can lead to neuronal swelling and brain edema that 
eventually leads to neurological injury.9
Injury From Immune-Mediated Response
Principally because of cytokine storms including 
enhanced levels of inflammatory cytokines and activation 
of macrophages, T lymphocytes, and endothelial 
cells, immune-mediated injury. Additional release of 
interleukins 6 generates activation of the complement 
and coagulation cascade, vascular leakage, dissemination 
of intravascular coagulation, and end-organ injury.17,18
Neurological Manifestations of COVID-19 
General Neurological Manifestations
Considering the global existence of SARS-CoV-2, it is 
surprising that no large-scale observational investigations 
are exploring the presence of the new coronavirus on the 
CNS. Many different case reports are indicating that some 
cases show neuropsychiatric virus symptoms such as 
impaired awareness and encephalopathy; however, these 
cases are limited by their strength.19 Since the initiation 
of the SARS-CoV-2 pandemic, most centers in China 
have been available from the limited published studies. 
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An early study of 214 hospitalized patients with SARS-
CoV-2 from the city of Wuhan, China, indicated that 
above a third (36.4%) of cases had a range of neurological 
impairment indicating that the aforementioned could be 
an understated aspect of the course of the disease.20 At 
3% and 0.5% sequentially, the occurrence of more serious 
neurological sequelae such as cerebrovascular injuries 
and seizures was small. This was found that people with 
“serious” SARS-CoV-2 infections are further expected to 
experience the neurological problems; nevertheless, the 
authors did not explain the criteria for discriminating 
between a severe from non-severe SARS-CoV-2 
infection.14 Figure 2 illustrate the common neurological 
manifestation of COVID-19.
Ironically, they observed that the greatest neurological 
symptoms happened beginning in the disease and may 
serve as a major early indicator of potential clinical 
worsening. Another related retrospective study by 
Chen et al from China identified that the symptoms of 
headache (8%) and confusion (9%) were mentioned by 
these patients; though, notably, neurological problems 
were substantially less common than the usual respiratory 
symptoms of dyspnoea (31%) and cough (82%).20,21 In a 
survey of 221 patients, Li et al demonstrated more serious 
and possibly long-lasting neurological effects of SARS-
CoV-2, and 6 percent experienced extreme neurological 
disorder: cerebral vein thrombosis hemorrhage, ischemic 
stroke, which resulted in a large proportion of deaths.11 
The neurological complications, signs, and symptoms of 
COVID-19 can be classified into peripheral and central as 
discussed in Table 1.
Central Nervous System Manifestations 
Encephalopathy 
In 40% of cases in their study, Mao et al stated 
encephalopathy and headache but the specifics and 
diagnostic tests used were not reported.11 Filatov et al19 
documented a male patient of a 74-year-old with a past 
medical history of stroke, atrial fibrillation, Parkinson 
disease, recent cellulitis, and chronic obstructive 
pulmonary disease who showed fever to the emergency 
ward. The initial diagnostic workup did not recommend 
any dangerous problem and he was released back, home. 
He came back with more severe symptoms, including 
fever, headache, and cough. Chest X-ray was pneumonia 
indicative, while the brain CT scan has not anything special 
except for symptoms of a past stroke. Polymerase chain 
reaction (PCR) of the cerebrovascular fluid test revealed 
the absence of infection. Since suffering respiratory failure, 
his test was confirmed for COVID-19 and intubated. He 
began on lopinavir/ritonavir, hydroxychloroquine, and 
proceeded on antibiotics of a broad range. 
Chen et al has reported hypoxic encephalopathy in 20 
patients in a retrospective review of the clinical features of 
113 COVID-19 cases from China.20 Among the recovered 
patients the rate was slightly lower.
Acute Hemorrhagic Necrotizing Encephalopathy 
The initial patient of COVID-19 – induced acute 
hemorrhagic necrotizing encephalopathy (ANE) from 
the US was identified by Poyiadji and colleagues.21 During 
her late fifties, a female patient had a 3-day history of 
fever, cough, and altered mental state. The PCR assay 
was convincing for COVID-19 and negative for West 
Nile, herpes simplex virus 1 and 2, and  varicella-zoster 
virus. For a typical CT venogram, and CT angiogram, 
the non-contrast brain CT images showed symmetrical 
hypoattenuation inside the bilateral medial thalami. 
Magnetic resonance imaging (MRI) brain revealed 
hemorrhagic surface enhancing lesions in the bilateral 
thalami, medial temporal lobes, and sub-insular areas. She 
was initiated on intravenous immunoglobulin (IVIG), but 
no mention was made of the result. ANE is an unusual 
complication of these influenza virus infections. The 
mechanism proposed is expected because of the cytokine 
storm which ends in blood-brain barrier disturbance and 
brain parenchyma injury.
Acute Myelitis 
Zhao et al confirmed acute myelitis in a city of Wuhan, 
a 66-year-old man, who had body aches and fever.22 He 
experienced bilateral lower limbs acute flaccid paralysis, 
the sensory level at T-10 during admission with bowel 
and urinary incontinence. The PCR test which was taken 
from the nasopharyngeal tract by a swap was positive for 
COVID-19 infection and a chest CT scan revealed patchy 
pneumonia. His serology had been negative for all other 
organisms.
Table 1. Neurological Manifestation of COVID-19 Categorized by the Site 
of Involvement



















                                                    Int Clin Neurosci J. Vol 7, No 4, Autumn 2020 167
                                                                                              COVID-19 Neurological Manifestation
journals.sbmu.ac.ir/Neurosciencehttp
Empirically he has undergone treating with IVIG, 
hormones, antibiotics, and antivirals. The reaction to 
the treatment was stable, and he was released for further 
recovery to an isolation unit. The authors contributed 
elevated levels of C-reactive protein, serum ferritin, serum 
amyloid-A, and interleukin-6 which leads to the cytokine 
storm and over activation of inflammatory reaction. The 
shortage of cerebrospinal fluid (CSF) PCR for coronavirus 
and spine MRI due to an outbreak in China is a significant 
shortcoming of this case study.
Cerebrovascular Accident 
Sharifi-Razavi et al from Iran described intracranial 
bleed cases ending in CVA in a 79-year-old positive 
male COVID-19.23 In the hospital, he was admitted to a 
semi-conscious status (Glasgow Coma Scale 7/15) with 
fever and cough previous history. Two-sided extensor 
plantar response with harsh crepitation in lower left 
zones was assessed. PCR nasopharyngeal secretion assay 
for COVID-19 was successful. A chest CT scan revealed 
a possible persistence of viral pneumonia in ground 
glass. A brain CT scan has shown a huge intraventricular 
and subarachnoid extension bleeds within the right 
hemisphere. This man was not a known hypertensive, 
nor was he on any anticoagulants that could have 
triggered this incident. On admission the platelets and 
the prothrombin time (PT)/international normalized 
ratio (INR) were regular. The authors hypothesized that 
possibly dysregulation in the reception tors of ACE-2 may 
have resulted in the bleeding of cerebral autoregulation, 
sympathy-adrenal system, and cerebral blood flow. 
Another thing that’s hard to understand is the nearly 
normal blood pressure at the time of admittance in this 
case. Mao et al in their cohort of 214 reported 6 CVA cases 
(5 ischemic cases and 1 hemorrhagic stroke).11 
A French cohort study with three cases of ischemic 
strokes that were observed on neuroimaging when 
encephalopathy imaging was undertaken by patients.12 
The patients lacked focal neurological signals. The signs 
have possibly been obscured due to the existence of 
encephalopathy, though it highlights the significance of 
neuroimaging in determining these cases. But there is a 
need for more evidence to determine a causal association 
within COVID-19 and stroke.
Encephalitis 
Moriguchi et al primarily documented the validated case 
of Japanese COVID-19 associated viral encephalitis.24 A 
present 24 years old gentleman with fever accompanied 
by coma and unconsciousness. He had stiffness of the 
neck and had a normal CT scan brain. Patchy pneumonia 
was present on the CT chest. The nasopharyngeal swab 
PCR assay was negative but COVID-19 was positive 
with the CSF sample. The diffusion-weighted images 
(DWI) showed hyperintensity along the right lateral 
ventricle lower horn wall. Hyperintense sign alterations 
in the right mesial temporal lobe and hippocampus 
with mild hippocampal atrophy were seen primarily on 
the hippocampus and right mesial lobe. There was no 
enhancement from post-contrast. The authors assumed 
that the conclusions of the imaging indicated encephalitis 
and right lateral ventriculitis. This patient and presentation 
will warn clinicians about COVID-19’s neuroinvasive 
potential and similar presentation of encephalitis.
Dizziness and Headaches  
Dizziness and headaches are a symptom of many diseases 
which is not clear and mild. They have been identified 
as mild symptoms correlated with COVID-19 being 
described in several studies. The incidence increases25-27 
from 3% to 12.1%. In none of these studies, the exact 
mechanism and pathophysiology are presented.
Peripheral Nervous System Manifestations and 
Complications 
Chemosensory Dysfunction and Anosmia 
Applying an internet-based cross-sectional 
questionnaire,28 Yan et al from the United States reported 
 
 




























Figure 2. General Neurological Symptom of COVID-19.
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chemosensory dysfunction in 59 COVID-19 positives 
and 203 COVID-19 negative patients from one center. 
They showed that in COVID-19 positive cases, the odor 
and taste dysfunction were higher compared to negative 
cases (Loss of smell: 68% vs. 16%, and loss of taste: 
71% vs. 17%). Many of the cases in this investigation 
were outpatient, they did not need hospitalization and 
mechanical ventilation was not needed. They theorized 
that the virus potentially spreads through the nasal 
route in ambulatory COVID-19 patients relative to 
critically ill patients where the spread is most convincing 
pulmonary. Bagheri et al published results of a broad 
Iranian cohort study of 10 069 patients using a survey 
focused on on-line questionnaires.29 Lately (in the last 40 
weeks of the COVID-19 outbreak in Iran) participants 
have been cases with issues with a reduced sense of 
smell. 48.23 percent of respondents reported anosmia 
and hyposmia while 83.38% also had a reduced sense of 
taste. Anosmia unexpectedly started at 76.24%. Certain 
clinical characteristics identified by the cooperators 
were pre-anosmia cold or flu symptoms (75.5%), fever 
(37.3%), nasal stiffness (43.7%), and headaches (48.6%). 
In comparison, Mao and colleagues’ study of 214 Chinese 
patients in their cohort recorded taste impairment in 12 
(5.6%) and smell impairment in 11 (5.1%) patients. The 
French cohort study of COVID-19 cases did not confirm 
anosmia and taste dysfunction.11
Guillain-Barre Syndrome 
Eight patients of Guillain-Barre syndrome (GBS) 
associated with COVID-19 have so far been published 
from Wuhan, China, Italy, and Iran. In a 61-year-old 
woman who had traveled to Wuhan city, China, Zhao et al 
published the first case of GBS.30 She had acute fatigue in 
both legs and extreme tiredness, improving within 1 day. 
Electromyography (EMG) and nerve conduction studies 
(NCS) are indicative of polyneuropathy demyelination. 
She underwent treatment with IVIG, and the respiratory 
problems emerged later. Her nasopharyngeal PCR test 
was positive for COVID-19. She transmitted the virus 
to two of her relatives and eight others including two 
neurologists and six isolated nurses who were found 
positive for COVID-19. The investigator assumed that 
a para-infectious model of GBS due to COVID-19 is 
consistent with the thrombocytopenia, travel history, 
and lymphopenia at the time of entry. Upon isolating and 
administering the antivirals, she made a successful motor 
recovery. 
Sedaghat and Karimi published Iranian diabetes patients 
of a 61-year-old male.31 Two weeks before presenting 
with ascending paralysis presented with bilateral facial 
paralysis and quadriplegia, he had a fever, cough, and 
occasionally dyspnea. EMG/NCS was indicative of 
sensory-axonal acute motor neuropathy. He had been 
operated by IVIG. The authors proposed that GBS should 
be thought a COVID-19 neurological complexity as the 
normal respiratory function in COVID-19 and may 
be a risk factor for GBS growth. Virani and colleagues 
published GBS in an American male of 54-years.32 He 
presented with quickly advancing distally to proximal 
paralysis starting the difficulty of breathing. There were 
no dysfunctions in the bladder or intestine. No reflexes 
and the spine were natural for MRI. 
He had a past medical history of diarrhea that followed 
an intense weakness attack. He screened COVID-19 for 
positive. He was treated with anti-malarial and IVIG. 
He replied well, and the ventilator was detached. He was 
moved to a physical therapy rehabilitation center. 
Five GBS patients from northern Italy were documented 
in Toscano et al.33 The major presenting characteristics in 
four patients were lower-limb paresthesia and weakness, 
accompanied by ataxia, paresthesia, and facial weakness in 
one patient. Four had positive PCR at the initial visit from 
the nasopharyngeal swab and fifth was initially negative 
but later turned positive. Patients with demyelinating 
polyneuropathy had features on NCS/EMG 02 while 
three had axonal polyneuropathy. All the patients have 
had IVIG therapy. This was replicated in 2 patients, 
and plasma was traded for one patient. Just one subject 
was able to ambulate spontaneously after one week and 
was released from the hospital. To confirm this classic 
relationship amid COVID-19 and GBS further large-scale 
studies are needed.
Skeletal Muscle Damage 
In 17 (19.3%) cases in the seriously ill and 6 (4.8%) cases 
in the non-severe category,11 Mao et al reported skeletal 
muscle lesion. Skeletal muscle damage was identified as 
a subject with raised serum creatine kinase level beyond 
200 U/L and myalgia. Researchers settled that it was not 
obvious whether this was due to the direct muscle tissue 
effect of the virus or other subsequent reasons. Another 
potential mechanism suggested was the infection-
mediated immune response that induced raised serum 
pro-inflammatory cytokines resulting in damage to the 
skeletal muscles.34,35 It should be remembered, however, 
that in addition to increased muscle enzymes, patients 
in the seriously ill the community also had raised liver 
enzymes and disordered renal functions that may 
have driven to this clinical feature.36,37 Besides, no clear 
confirmatory diagnostic study such as NCS/EMG or 
muscle cell histopathology has been done.38 Therefore it 
is difficult to exclude that in addition to skeletal muscle 
injury, these patients may have essential disease myopathy 
and neuropathy.
Conclusion 
COVID-19 fundamentally alters the function of 
cardiovascular and respiratory systems. Neurological 
impairments, however, is not rare and can lead to severe 
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complexities if not identified and handled quickly. Such 
complications are often seen in cases with a serious disease 
and can also precede the respiratory symptoms in some 
cases or even maybe the solitary symptoms in COVID-19 
subjects. Consequently, when dealing with these cases, a 
great index of mistrust is needed for immediate treatment 
and prevention. It is further necessary to regularly collect 
data from various parts of the world on long and short-
term neurological complications and to track the practical 
outcomes of these complexities.
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